MacLean Ashley J B, Schwartz Thomas L
Department of Psychiatry, SUNY Upstate Medical University, Syracuse, NY, USA.
Expert Rev Neurother. 2015 May;15(5):469-75. doi: 10.1586/14737175.2015.1034693. Epub 2015 Apr 20.
Tramadol is a novel, synthetic opioid receptor agonist with serotonin-norepinephrine reuptake inhibitor properties that is often prescribed acutely for painful conditions. Fibromyalgia (FM) is a chronic painful condition that is difficult to treat and until more recently has had no approved medical treatments. Currently, the only US FDA-approved medications for FM include duloxetine, milnacipran and pregabalin. No opioid is approved for use in the treatment of FM. This paper specifically reviews the literature on tramadol use in FM and concludes that there is a fair evidence base to support its use as a second-line treatment for more resistant cases.
曲马多是一种新型合成阿片受体激动剂,具有5-羟色胺-去甲肾上腺素再摄取抑制特性,常用于急性疼痛状况的处方。纤维肌痛(FM)是一种慢性疼痛病症,难以治疗,直到最近尚无获批的药物治疗方法。目前,美国食品药品监督管理局(FDA)唯一批准用于纤维肌痛治疗的药物包括度洛西汀、米那普明和普瑞巴林。尚无阿片类药物获批用于纤维肌痛的治疗。本文专门回顾了关于曲马多用于纤维肌痛治疗的文献,并得出结论:有充分的证据支持将其用作更难治性病例的二线治疗药物。